142 related articles for article (PubMed ID: 12413427)
1. Development of hammerhead ribozymes to modulate endogenous gene expression for functional studies.
Fritz JJ; Lewin A; Hauswirth W; Agarwal A; Grant M; Shaw L
Methods; 2002 Oct; 28(2):276-85. PubMed ID: 12413427
[TBL] [Abstract][Full Text] [Related]
2. Experimental cancer gene therapy by multiple anti-survivin hammerhead ribozymes.
Fei Q; Zhang H; Fu L; Dai X; Gao B; Ni M; Ge C; Li J; Ding X; Ke Y; Yao X; Zhu J
Acta Biochim Biophys Sin (Shanghai); 2008 Jun; 40(6):466-77. PubMed ID: 18535745
[TBL] [Abstract][Full Text] [Related]
3. Synthetic hammerhead ribozymes as therapeutic tools to control disease genes.
Citti L; Rainaldi G
Curr Gene Ther; 2005 Feb; 5(1):11-24. PubMed ID: 15638708
[TBL] [Abstract][Full Text] [Related]
4. Design and validation of therapeutic hammerhead ribozymes for autosomal dominant diseases.
Fritz JJ; Gorbatyuk M; Lewin AS; Hauswirth WW
Methods Mol Biol; 2004; 252():221-36. PubMed ID: 15017052
[TBL] [Abstract][Full Text] [Related]
5. Tetracycline-regulated expression of hammerhead ribozymes in vivo.
Bowden ET; Riegel AT
Methods Mol Biol; 2004; 252():179-94. PubMed ID: 15017049
[TBL] [Abstract][Full Text] [Related]
6. Hammerhead ribozymes for target validation.
Goodchild J
Expert Opin Ther Targets; 2002 Apr; 6(2):235-47. PubMed ID: 12223083
[TBL] [Abstract][Full Text] [Related]
7. Repression of hepatitis B virus X gene expression by hammerhead ribozymes.
Kim YK; Junn E; Park I; Lee Y; Kang C; Ahn JK
Biochem Biophys Res Commun; 1999 Apr; 257(3):759-65. PubMed ID: 10208856
[TBL] [Abstract][Full Text] [Related]
8. Design and production of asymmetric hammerhead ribozymes.
Tabler M; Sczakiel G
Methods Mol Biol; 1997; 74():141-9. PubMed ID: 9204429
[No Abstract] [Full Text] [Related]
9. Hammerhead ribozymes selectively suppress mutant type I collagen mRNA in osteogenesis imperfecta fibroblasts.
Dawson PA; Marini JC
Nucleic Acids Res; 2000 Oct; 28(20):4013-20. PubMed ID: 11024182
[TBL] [Abstract][Full Text] [Related]
10. Hammerhead ribozymes reduce central nervous system (CNS)-derived neuronal nitric oxide synthase messenger RNA in a human cell line.
Maniotis D; Wood MJ; Phylactou LA
Neurosci Lett; 2002 Aug; 329(1):81-5. PubMed ID: 12161268
[TBL] [Abstract][Full Text] [Related]
11. Effective anti-hepatitis B virus hammerhead ribozymes derived from multimeric precursors.
Weinberg MS; Ely A; Passman M; Mufamadi SM; Arbuthnot P
Oligonucleotides; 2007; 17(1):104-12. PubMed ID: 17461767
[TBL] [Abstract][Full Text] [Related]
12. Automated design of hammerhead ribozymes and validation by targeting the PABPN1 gene transcript.
Kharma N; Varin L; Abu-Baker A; Ouellet J; Najeh S; Ehdaeivand MR; Belmonte G; Ambri A; Rouleau G; Perreault J
Nucleic Acids Res; 2016 Feb; 44(4):e39. PubMed ID: 26527730
[TBL] [Abstract][Full Text] [Related]
13. Anti-gene therapy: the use of ribozymes to inhibit gene function.
Couture LA; Stinchcomb DT
Trends Genet; 1996 Dec; 12(12):510-5. PubMed ID: 9257533
[TBL] [Abstract][Full Text] [Related]
14. RNA hairpin loops repress protein synthesis more strongly than hammerhead ribozymes.
Drew HR; Lewy D; Conaty J; Rand KN; Hendry P; Lockett T
Eur J Biochem; 1999 Nov; 266(1):260-73. PubMed ID: 10542074
[TBL] [Abstract][Full Text] [Related]
15. Development of lead hammerhead ribozyme candidates against human rod opsin mRNA for retinal degeneration therapy.
Abdelmaksoud HE; Yau EH; Zuker M; Sullivan JM
Exp Eye Res; 2009 May; 88(5):859-79. PubMed ID: 19094986
[TBL] [Abstract][Full Text] [Related]
16. Hammerhead ribozymes targeted to the FBN1 mRNA can discriminate a single base mismatch between ribozyme and target.
Phylactou LA; Tsipouras P; Kilpatrick MW
Biochem Biophys Res Commun; 1998 Aug; 249(3):804-10. PubMed ID: 9731217
[TBL] [Abstract][Full Text] [Related]
17. Designing and characterizing hammerhead ribozymes for use in AAV vector-mediated retinal gene therapies.
Fritz JJ; White DA; Lewin AS; Hauswirth WW
Methods Enzymol; 2002; 346():358-77. PubMed ID: 11883079
[No Abstract] [Full Text] [Related]
18. The 5'-end of hTERT mRNA is a good target for hammerhead ribozyme to suppress telomerase activity.
Yokoyama Y; Takahashi Y; Shinohara A; Wan X; Takahashi S; Niwa K; Tamaya T
Biochem Biophys Res Commun; 2000 Jun; 273(1):316-21. PubMed ID: 10873604
[TBL] [Abstract][Full Text] [Related]
19. Attenuation of telomerase activity by hammerhead ribozymes targeting human telomerase RNA and telomerase reverse transcriptase in pancreatic carcinoma cells.
Hayashidani Y; Hiyama E; Murakami Y; Sueda T
Hiroshima J Med Sci; 2005 Mar; 54(1):21-7. PubMed ID: 15847061
[TBL] [Abstract][Full Text] [Related]
20. Engineering high-speed allosteric hammerhead ribozymes.
Link KH; Guo L; Ames TD; Yen L; Mulligan RC; Breaker RR
Biol Chem; 2007 Aug; 388(8):779-86. PubMed ID: 17655496
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
